Daniel Di Renzo
About Daniel Di Renzo
Daniel Di Renzo is a Director at Arcus Biosciences in Hayward, California, where he has worked since 2023. He has a background in cellular and molecular biology, holding a PhD from Purdue University and has held various research positions at notable institutions including Stanford University and the University of Wisconsin-Madison.
Current Role at Arcus Biosciences
Daniel Di Renzo currently serves as Director at Arcus Biosciences in Hayward, California. He has held this position since 2023. In this role, he oversees various projects and initiatives within the organization, contributing to the development of innovative cancer therapies.
Previous Experience at Arcus Biosciences
Prior to his current role, Daniel Di Renzo worked at Arcus Biosciences as a Principal Investigator from 2020 to 2021. He later served as a Research Fellow from 2021 to 2023. His work during these periods focused on advancing research and development in cancer immunotherapy.
Educational Background
Daniel Di Renzo earned his Doctor of Philosophy (PhD) in Cell/Cellular and Molecular Biology from Purdue University, where he studied from 2006 to 2012. He also holds a Bachelor of Science in Biology from the University at Albany, SUNY, completed between 2002 and 2005.
Postdoctoral Training
Daniel Di Renzo completed his postdoctoral training at Stanford University from 2014 to 2016 and at the University of Wisconsin-Madison from 2012 to 2014. These experiences provided him with advanced research skills and expertise in cellular and molecular biology.
Research Contributions
Daniel Di Renzo has co-authored significant research presented at major conferences. His work includes methods for assessing the 'adenosine fingerprint' in clinical trials of etrumadenant, presented at the Annual Meeting of the American Association of Cancer Research (AACR). He also contributed to research on the anti-tumor efficacy of immunogenic chemotherapy enhanced by the dual A2aR/A2bR antagonist etrumadenant, presented at the Society for Immunotherapy of Cancer (SITC).